Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triamcinolone hexacetonide is a synthetic glucocorticoid corticosteroid used primarily for its potent anti-inflammatory and immunosuppressive effects. It is a long-acting derivative of triamcinolone, formulated as an injectable suspension for intra-articular, intralesional, or soft tissue administration. The drug works by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability, thereby reducing inflammation and immune responses in various tissues. Triamcinolone hexacetonide is indicated for the treatment of inflammatory joint disorders such as rheumatoid arthritis, psoriatic arthritis, osteoarthritis (especially knee and shoulder), acute gouty arthritis, bursitis, tenosynovitis, epicondylitis; as well as dermatologic conditions like alopecia areata, discoid lupus erythematosus, keloids, granuloma annulare lesions, lichen planus/lichen simplex chronicus (neurodermatitis), psoriatic plaques; necrobiosis lipoidica diabeticorum; and cystic tumors such as ganglia[1][5][6]. Its slow absorption from injection sites provides prolonged local action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone hexacetonide.